Read this information carefully before using this medicine.
Ask your doctor or pharmacist if you need further information.
Registration License No САМ N1383IP-15
Trade name: Tenoten
Pharmaceutical form: Orodispersible tablets.
Composition: Each orodispersible tablet contains:
Active ingredient: Affinity purified antibodies to brain specific S-100 protein − 3 mg*.
Excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate.
* Water-ethanol mixture of the active substance dilutions with concentration not more than 10-15 ng/g used for saturation of lactose monohydrate.
White to off-white, round, flat, scored on one side and beveled tablets, marked MATERIA MEDICA on one side and TENOTEN on the other.
ATC codes: N05BX, N06BX.
The medicine has a sedative, antianxiety (anxiolytic) action, producing no undesirable hypnogenic and myorelaxant effects. Tenoten promotes tolerance to psychoemotional stress. It has stress-protective, nootropic, antiamnestic, antihypoxic, neuroprotective, antiasthenic, and antidepressant effects.
In conditions of intoxication, hypoxia, and states following acute cerebral circulation impairment, the medicine produces a neuroprotective effect, limits the damage area, and restores learning and memory processes in the central nervous system (CNS).
Tenoten inhibits lipid peroxidation.
It modifies the functional activity of S-100 proteins responsible for the integration of metabolic and synaptic (information transmission) processes. By exerting GABA-mimetic and neurotrophic effects, Tenoten enhances the activity of stress-limiting systems and promotes neuronal plasticity restoration.
Pharmacokinetics: The sensitivity of contemporary physicochemical methods (gas-liquid chromatography, high performance liquid chromatography and mass spectrometry) does not allow to assess the content of ultralow doses of antibodies in biological fluids, organs and tissues; that makes technically impossible to investigate the pharmacokinetic properties of Tenoten.
Neurotic and neurosis-like states, psychosomatic conditions, stress-induced disorders coupled with increased nervous strain, irritability, anxiety, and autonomic responses.
Moderate organic damage to the CNS (including that caused by injury or cerebral circulatory disorder) accompanied by emotional lability, irritability, memory decline, and autonomic disturbances.
Individual hypersensitivity to any of the medicine components; children aged under 18 years. Children and individuals younger than 18 years of age are prescribed to use Tenoten for Children.
Posology and method of administration
One or two tablets per intake (the tablet should be held in the mouth until it is completely dissolved, not during the meal).
Daily dosage: 2 intakes per day; if necessary, up to 4 intakes per day. Treatment duration: 1-3 months; if appropriate, treatment with Tenoten may be continued up to 6 months or repeated after a 1-2 month period.
If no sustainable improvement is achieved within 3-4 weeks of treatment initiation, medical care should be sought.
No side effects have been reported for the medicine used in accordance with the specified indications in the recommended doses.
Individual hypersensitivity to components of the medicine is possible.
Inform doctors of any unwanted effects related to drug use.
No cases of overdose have been reported.
Effects on ability to drive and use machines
Tenoten has no influence on the ability to drive and use machines.
Interaction with other medicinal products and other forms of interaction
Cases of incompatibility with other medicines have not been reported.
Special warnings and precautions for use
Medicine contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Due to the presence of activating properties in Tenoten's activity range, the last daily dose should not be taken later than 2 hours before bed time.
Use in Pregnancy and lactation
There were no special clinical studies of Tenoten on woman in period of pregnancy or lactation.
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition of postnatal development.
Caution should be exercises when prescribing to pregnant women.
Nature and contents of container
20 orodispersible tablets in PVC/Aluminum blister. 2 blisters are inserted into a cardboard box with leaflet.
Store in dry light-protected place at temperature below 30 0C.
Store in the original package.
Keep out of reach of children.
Over the counter.
3 years since the manufacturing date. Do not use after the expiry date indicated on the package.
Specification: Manufacturer’s standard (In-house).
ООО “NPF “MATERIA MEDICA HOLDING”
9, 3rd Samotyochny per., Moscow, Russia, 127473
Tel./Fax: +7 (495) 684-43-33